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Summary: The relationship between the eosinophil concentration and the serum eosinophil protein X concentration
was investigated in 80 subjects. Higher eosinophil counts resulted in obviously increased serum eosinophil protein
X concentrations. However, the amount of eosinophil protein X released per eosinophil granulocyte is significantly
higher in subjects with lower eosinophil counts.
Atopic subjects (N = 19) show a significantly higher eosinophil concentration (p = 0.002) and eosinophil protein
X concentration (p = 0.004) and a significantly lower eosinophil protein X/eosinophil ratio (p = 0.02), compared
with non-atopic subjects (N = 61). However, there appears to be no difference between the concentration of eosino-
phil protein X in atopic and non-atopic subjects if the eosinophil concentration is taken into account. When using
eosinophil protein X as an indicator of eosinophil activation, for instance in asthmatic subjects, the eosinophil count
should also be considered for correct clinical interpretation of results.
Introduction
Eosinophils play an important role in the immune
response to parasites and in the pathogenesis of certain
inflammatory diseases, especially asthma. The granules
of the eosinophil granulocytes contain a number of
highly cationic proteins, which are released following
activation and stimulation of the eosinophil. Release
of granule proteins from eosinophils is a selective
phenomenon with respect to the individual proteins
(1). Several proteins have been characterized, includ-
ing eosinophil cationic protein and eosinophil protein
X, which is synonymous with eosinophil-derived
neurotoxin (2). Eosinophil cationic protein and eosino-
phil protein X are single chain proteins with relative
molecular mass in the range of MT 18000—Mr 21 000
and pi > 11 and pi > 9, respectively (2). The measure-
ment of eosinophil-derived proteins such as eosinophil
protein X in biological fluids may be a useful indica-
tor of eosinophil activation.
Eosinophil protein X has a lower pi than eosinophil cat-
ionic protein, so that eosinophil protein X adheres less
than eosinophil cationic protein to cell-membranes after
degranulation. Eosinophil protein X might therefore be
a more suitable marker for measuring the state of activa-
tion of the eosinophil.
Reported ranges of eosinophil protein X concentrations
in serum have varied widely over the years and they
show large deviations between laboratories (3, 4). In the
measurement of eosinophil-derived proteins in serum it
is particularly important to standardize the handling of
the blood samples (7—10). Previous studies have shown
that serum concentrations of eosinophil granule proteins
are related to the severity of asthma (5, 6) and may pro-
vide an additional tool for monitoring the efficacy of
anti-inflammatory therapy.
In this study the relationship between eosinophil con-
centration and the serum eosinophil protein X concen-
tration under standardized conditions is established.
Furthermore, atopic and non-atopic subjects within this
group are compared, in order to establish differences in
eosinophil concentration, eosinophil protein X concen-
tration and eosinophil protein X concentration recorded
per eosinophil.
Materials and Methods
Blood samples were taken from 80 apparently healthy adults
(males and females, aged 18—60 year). From each subject two
serum samples (Vacutainer, ref. 367783, with addition of SST
gel and clot activator, Becton Dickinson, Plymouth, UK) and
one plasma sample (Vacutainer, ref. 367652, with addition of
K3EDTA as an anti-coagulant, Becton Dickinson, Plymouth, UK)
were obtained. After venepuncture, blood samples were clotted
for 60 ± 10 minutes in a waterbath of 37 °C. After clotting,
blood samples were centrifuged at room temperature for 10
minutes at 1350g. Subsequently the serum samples were stored
at —20 °C until the serum eosinophil protein X concentration
was measured. Serum eosinophil protein X concentrations were
established with a radioimmunoassay kit (Kabi Pharmacia, Upp-
sala, Sweden), with an inter-assay coefficient of variation of
4.8-10.6% as specified by the manufacturer. This range was
confirmed by our own experiments. For the eosinophil protein
X concentration a detection limit of 3 g/l was established. Eo-
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sinophil concentrations in blood samples were determined with a
Sysmex NE-8000 haematology analyser (Charles Goffin Medical
Systems BV, Tiel, The Netherlands).
IgE concentrations and determination of IgE antibodies specific to
inhalant allergens were measured with a radioimmunoassay kit
(Total IgE & Phadiatop; Kabi Pharmacia, Uppsala, Sweden).
Statistics
The statistical significance of the regression coefficient showing
the correlation between eosinophil count and eosinophil protein X
concentration was established by multiple regression analysis, in
order to test the statistical significance of differences between the
subject groups on the basis of eosinophil concentrations, the Mann-
Whitney-U test was applied. This test was also used to determine
statistical differences between atopic and non-atopic individuals.
Results
Eosinophil protein X concentrations determined for dif-
ferent eosinophil counts are depicted in figure 1. It is
apparent from figure 1 that the eosinophil protein X con-
centration increased significantly with higher eosinophil
counts. Subsequently, the mean quantity of eosinophil
protein X released per eosinophil was calculated. The
whole group (N = 80) was divided into four groups with
eosinophil concentrations of 0-0.10 X 109/1 (N = 29),
0.11-0.20 X 109/1 (N = 23), 0.21-0.30 X 109/1
(N = 17) and 0.31-0.80 X 109/1 (N = 11). For each
group the median of the eosinophil protein X/eosinophil
ratio was calculated. Results are depicted in figure 2. A
statistically significant increase was found in the eosino-
phil protein X/eosinophil ratio in subjects with lower
eosinophil counts.
Total IgE concentrations and concentrations of IgE spe-
cific to inhalant allergens were determined in the serum
samples from 80 apparently healthy subjects. A subject
is considered to be atopic when the IgE concentration is
above 120 kIU/1 (11, 12) and the result for IgE specific
for inhalant allergens is positive. Within the 80 subjects,






















Results of application of the Mann-Whitney U-Wilcoxon rank sum
test, in order to establish statistically significant differences be-
tween the groups of atopic (N = 19) and non-atopic (N = 61) sub-
jects. A statistically significant difference is considered to be pre-
sent when the p-value is < 0.05.
who were all without allergic complaints, 10 (25%) were
classified as atopic by application of the criteria men-
tioned above. The eosinophil concentration, eosinophil
protein X concentration and eosinophil protein X/eosi-
nophil ratio of both groups are reported in table 1.
The eosinophil concentrations are significantly higher in
the atopic subjects (median = 0.23 X 109/1) than in the
non-atopic subjects (median = 0.11 X 109/1, ρ = 0.002).
Eosinophil protein X concentrations are significantly
higher in the atopic group (median = 69 μg/l) in com-
parison with the non-atopic group (median =41 μg/l,
ρ = 0.004). The eosinophil protein X/eosinophil ratios
are significantly lower in the atopic group (median
= 165 μg/109) than in the non-atopic group (median
= 214 μg/109, ρ = 0.02).
Discussion
The eosinophil protein X content of eosinophil granulo-
cytes is estimated to be about 17 μg/106 eosinophils
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Fig. 1 Eosinophil protein X concentrations determined in sam-
ples clotted at 37 °C versus eosinophil granulocyte counts in 80
subjects. Black circles represent values for samples of the non-
atopic individuals. Open circles show results from samples of the
atopic subjects.
Results of statistical analysis:
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Fig. 2 Median values (horizontal line inside the box) for the
eosinophil protein X/eosinophil ratio in 4 groups representing
different ranges for eosinophil concentrations. Boxes indicate the
25th and 75th percentiles. The length of the tail, which is a
measure of the scattering of results, is shown by the upper and
lower lines.
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(13). When considering this estimate and the results of
our study, it should be emphasized that the release of
eosinophil protein X in serum during clotting at 37 °C
amounts to 0.3 to 2% of the total eosinophil protein X
content of eosinophils. As a consequence, the amount of
eosinophil protein X actually released in vitro is only a
small fraction of the total eosinophil protein X content
of eosinophils. A minimal fraction of the eosinophil pro-
tein X concentration in serum might be due to release
from neutrophil granulocytes. Compared with eosino-
phils, neutrophil granulocytes contain only a very small
quantity of eosinophil protein X, i.e. 1-2% of the
content of an eosinophil granulocyte (14).
Compared with eosinophil protein X, less eosinophil
cationic protein is released from eosinophils in vitro (9,
10). The various mechanisms by which eosinophils may
be activated and release their granule proteins are only
poorly understood. The reason for the differences be-
tween eosinophil cationic protein and eosinophil protein
X release is not yet elucidated. One possible explanation
may be the fact that eosinophil cationic protein tends
to stick more tightly to cell membranes than eosinophil
protein X because of the more basic character of eosino-
phil cationic protein. In addition, the release mecha-
nisms of these two granule proteins may be different
(1). Differences in the mechanisms and kinetics of the
clearance of these proteins from the circulation should
also be taken into consideration.
It has been demonstrated that eosinophil cationic protein
has the ability to bind to clotting factors (15). Particular
information concerning the interaction between clotting
and eosinophil protein X release after blood sampling is
not yet available. Because of the striking effect of the
temperature of serum preparation on in vitro release of
granule proteins (7—10), blood samples should be clot-
ted in our opinion at a precisely fixed temperature. We
prefer to clot blood samples at 37 °C. This temperature
results in a rather extended range of eosinophil protein
X concentrations in samples from different subjects,
which are still within the detection range of the kit.
In a previous study it was stated that eosinophils of al-
lergic patients excrete eosinophil protein X more readily
than eosinophils of healthy persons (13). In view of this
statement, it may be of clinical importance to calculate
the ratio of serum eosinophil protein X concentration
and the eosinophil concentration. When calculating this
ratio for apparently healthy subjects, we observed that
the amount of eosinophil protein X released per eosino-
phil showed a significant tendency to increase with
decreasing eosinophil counts. An explanation for this
observation might be that eosinophils in samples with a
rather high concentration are less primed than eosino-
phils in samples with lower concentrations of granulo-
cytes. The tendency towards higher eosinophil pro-
tein X/eosinophil ratios in the lower eosinophil count
ranges might be due inter alia to a bias caused by the
relatively high amount of eosinophil protein X which
has already been secreted 'in vivo' at 37 °C. Concerning
the laboratory procedure for measurement, the relatively
high eosinophil protein X/eosinophil ratio in the lower
eosinophil concentration range might be caused by inac-
curacy of the eosinophil count. However, experiments
on the effects of diluting the blood samples gave no
indication of a systemic deviation in the low eosinophil
count range.
With respect to the eosinophil concentration, it is con-
cluded that atopic individuals possess significantly
higher eosinophil concentrations than do non-atopic in-
dividuals. The eosinophil protein X concentration is also
significantly higher in the atopic group. Finally, the eo-
sinophil protein X/eosinophil ratio is significantly lower
in the atopic group than in the non-atopic group.
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